Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant epidermal growth factor - Center for Genetic Engineering and Biotechnology/Praxis Pharmaceuticals

Next Previous
Drug Profile

Recombinant epidermal growth factor - Center for Genetic Engineering and Biotechnology/Praxis Pharmaceuticals

Alternative Names: Heberprot-P; Heberprot-P 75; hrecEGF; rhEGF; rhuEGF

Latest Information Update: 06 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Center for Genetic Engineering and Biotechnology; Praxis Pharmaceuticals
  • Class Antiulcers; Growth factors
  • Mechanism of Action Epidermal growth factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Diabetic foot ulcer

Most Recent Events

  • 30 Apr 2024 The US FDA completes IND review of phase III trial in Diabetic foot ulcer
  • 30 Apr 2024 Discovery Therapeutics Caribe plans a pivotal phase III trial in Diabetic foot ulcer in the USA (Intralesional) by year-end 2024
  • 10 Apr 2024 Discovery Therapeutics Caribe receives study may proceed letter from the US FDA for phase III trial in Diabetic foot ulcer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top